Zobrazeno 1 - 10
of 94
pro vyhledávání: '"regdanvimab"'
Autor:
Soyoon Hwang, Nan Young Lee, Eunkyung Nam, Yu Kyung Kim, Shin-Woo Kim, Hyun-Ha Chang, Yoonjung Kim, Sohyun Bae, Juhwan Jeong, Jae-Ho Shin, Guehwan Jang, Changhee Lee, Ki Tae Kwon
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 5, Pp 1037-1050 (2024)
Abstract Introduction Regdanvimab, a monoclonal antibody pharmaceutical, is the first Korean drug approved for treating coronavirus disease 2019 (COVID-19). We analyzed the therapeutic efficacy of regdanvimab in patients with the COVID-19 delta varia
Externí odkaz:
https://doaj.org/article/fc336b99f98b4416b83955caf85b465c
Autor:
Youn Kyung Kee, Hayne Cho Park, Su Jin Yoon, Sungbong Yu, Eunsil Ko, AJin Cho, Do Hyoung Kim, Jinseog Kim, Young-Ki Lee
Publikováno v:
Kidney Research and Clinical Practice, Vol 43, Iss 1, Pp 111-121 (2024)
Background Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), there are lack of effective and proven treatments for end-stage renal disease (ESRD). The present study aims to evaluate the
Externí odkaz:
https://doaj.org/article/9c1efee305264f92a8819f46eee7d39d
Publikováno v:
International Journal of Infectious Diseases, Vol 130, Iss , Pp 94-100 (2023)
Objectives: To evaluate the efficacy and safety of regdanvimab, a neutralizing antibody, in patients with mild-to-moderate SARS-CoV-2 including against the Delta variant. Methods: A single-center, retrospective, observational cohort study in adults w
Externí odkaz:
https://doaj.org/article/1d71c40b49984eaea6e2579ec76be0c6
Autor:
Daria S. Fomina, Marina S. Lebedkina, Anna A. Iliukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Sergey S. Andreev, Anton A. Chernov, Inna V. Dolzhikova, Tatyana S. Kruglova, Gerelma V. Andrenova, Amir I. Tukhvatulin, Dmitry V. Shcheblyakov, Alexander V. Karaulov, Maryana A. Lysenko, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Several virus-neutralizing monoclonal antibodies (mAbs) have become new tools in the treatment of the coronavirus disease (COVID-19), but their effectiveness against the rapidly mutating virus is questionable. The present study investigated the effec
Externí odkaz:
https://doaj.org/article/670820e7fe5d4672ba2d2ca795a32834
Autor:
Daria Beshnova, Yan Fang, Mingjian Du, Yehui Sun, Fenghe Du, Jianfeng Ye, Zhijian James Chen, Bo Li
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 20, Iss , Pp 2212-2222 (2022)
Coronavirus disease 2019 (COVID-19) caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide as a severe pandemic and caused enormous global health and economical damage. Since December 2019, more than 197 m
Externí odkaz:
https://doaj.org/article/3de84621375e45db87efe2eaa98dbd43
Autor:
Haein Kim, Young Rock Jang, Ji Yeon Lee, Jae-Hoon Ko, Jee Young Lee, Seongcheol Cho, Yong Dae Lee, Junghoon Song, Miri Hyun, Hyun Ah Kim, Soyoon Hwang, Sangmi Ryou, Yoo Jin Na, Joo-Yeon Lee, Changhee Lee, Nan Young Lee, Seunghwan Shin, Ki Tae Kwon, Jin Yong Kim, Kyong Ran Peck
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 13 (2023)
BackgroundImmune-evading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are emerging continuously. The clinical effectiveness of monoclonal antibody agents that exhibit decreased in vitro activity against SARS-CoV-2 variants ne
Externí odkaz:
https://doaj.org/article/85adaa5567c544aab6c1b54e1b31918b
Autor:
Ulyana A. Markina, Daria S. Fomina, Marina S. Lebedkina, Tatiana S. Kruglova, Anton A. Chernov, Alena I. Zagrebneva, Zinaida Yu. Mutovina, Alexander V. Karaulov, Ekaterina I. Alexeeva, Mariana A. Lysenko
Publikováno v:
Терапевтический архив, Vol 94, Iss 5, Pp 675-682 (2022)
Background. The use of virus-neutralizing monoclonal antibodies is an effective method of etiotropic therapy for SARS-CoV-2 in patients of high-risk groups of severe COVID-19. Regdanvimab is a single-component monoclonal antibodies immunoglobulin G1,
Externí odkaz:
https://doaj.org/article/1ca7266523cb42cb8962e01de2e8c208
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Current Therapeutic Research, Vol 96, Iss , Pp 100675- (2022)
ABSTRACT: Background: In a Phase III study, regdanvimab (CT-P59) reduced the risk of hospitalization or death versus placebo in patients with mild-to-moderate coronavirus disease 2019 (COVID-19). Purpose: We performed a retrospective cohort study of
Externí odkaz:
https://doaj.org/article/6a046dd4333143e1b3fa0a2ebe91b0de
Autor:
Ji Yeon Lee, Jee Young Lee, Jae-Hoon Ko, Miri Hyun, Hyun Ah Kim, Seongcheol Cho, Yong Dae Lee, Junghoon Song, Seunghwan Shin, Kyong Ran Peck
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
ObjectiveTo evaluate clinical effectiveness of regdanvimab, a monoclonal antibody agent for treating coronavirus 2019 (COVID-19).MethodsA retrospective cohort study was conducted at two general hospitals during the study period of December 2020 to Ma
Externí odkaz:
https://doaj.org/article/49b7338baad74e2ebab519520a09a853